Clinical Trials
38 trialsDCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI
Tianjin Medical University Cancer Institute and Hospital
OMEC-5
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
INS-ESCC-CT
Sichuan University
CHANCES
Institut Paoli-Calmettes
PEGASUS
University Hospital Heidelberg
A Study of Bemosubaiabimab Combined With Anlotinib and Radiotherapy and Chemotherapy for the Treatment of Oligometastatic Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
SCR-ESCC-01
Shanghai Chest Hospital
ESO-Nanjing7
Jiangsu Cancer Institute & Hospital
Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age
The First Affiliated Hospital with Nanjing Medical University
AGAMENON
Fundación Sociedad Española de Oncologia Médica
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
Medical College of Wisconsin
TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)
University of Colorado, Denver
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Tianjin Medical University Cancer Institute and Hospital
ROOT
Taproot Health
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Henan Cancer Hospital
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Celldex Therapeutics
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Fudan University
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Tang-Du Hospital
Effect of NST Whole-course Nutritional Management on Nutritional Status and Adverse Reactions in Esophageal Cancer
The First Affiliated Hospital with Nanjing Medical University
Safety and Feasibility of Irradiation and Nivolumab in Esophageal Cancer (INEC)
Oslo University Hospital
CRATER
University of Kentucky
A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer
Zhejiang Cancer Hospital
A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION
Abramson Cancer Center at Penn Medicine
Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer
Henan Cancer Hospital
ES01
University of Florida
Neoadjuvant Chemotherapy Followed by Preoperative Chemoradiation in Resectable Squamous-cell Esophageal Cancer
Russian Academy of Medical Sciences
Positron Emission Tomography in Determining Stage of Esophageal Cancer
Alliance for Clinical Trials in Oncology
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus
Radiation Therapy Oncology Group
Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
National Cancer Institute (NCI)
Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus
Memorial Sloan Kettering Cancer Center
Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer
Fudan University
A Study to Evaluate the Combination of Cetuximab and Chemotherapy as Neoadjuvant Therapy Followed Concomitant Chemoradiotherapy Plus Cetuximab in Locoregional Esophageal Carcinoma
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
CRCRT-EC
Centre Oscar Lambret
COL06-13
Centre Oscar Lambret
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
FeRx